Investigators LYM-3001 Study

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

2011 | Lékařská fakulta v Hradci Králové

Publikace